Table 3
Inhibitory effects of C. setidens extract on the formation of advanced glycation end products (AGEs) in vitro
| Conc.(μg/mL) | Inhibition (%) |
| 500 | 250 | 125 | 62.5 | 31.3 | 15.6 | IC50 (μg/mL) |
| MeOHext. | 66.0±1.31) | 49.8±1.5 | 37.1±1.3 | 33.2±0.9 | 21.7±0.8 | 19.3±0.7 | 221.1±7.7 |
| n-Hexanelayer | 30.1±1.2 | 17.6±0.8 | 12.2±0.5 | 7.2±0.6 | 5.1±0.5 | 3.0±0.6 | >500 |
| EtOAclayer | 29.1±1.0 | 21.9±0.6 | 17.5±0.7 | 8.1±0.5 | 7.5±0.6 | 5.2±1.0 | >500 |
| n-BuOHlayer | 86.8±1.8 | 73.7±1.9 | 70.7±1.5 | 57.3±1.1 | 41.1±1.3 | 32.1±1.1 | 46.0±1.5 |
| H2Olayer | 62.2±2.5 | 55.6±1.3 | 23.0±0.8 | 19.6±0.9 | 10.1±0.8 | 5.1±0.6 | 272.3±4.1 |
| Aminoguanidine2) | 85.1±2.6 | 70.1±1.8 | 53.1±1.6 | 39.1±1.3 | 32.0±0.7 | 31.1±0.7 | 90.7±3.2 |
Inhibitory effects are expressed as the mean±SD of triplicate experiments.
Used as a positive control.